Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Covers use of injectable bulking agents for treatment of urinary and fecal incontinence — primarily periurethral injections for stress urinary incontinence and intrinsic sphincter deficiency (including post‑prostatectomy SUI) and the FDA‑approved NASHA‑Dx (Solesta) anal injection for passive fecal incontinence. Coverage is limited to FDA‑cleared/approved agents and indications (generally adults), excludes investigational materials and autologous/cellular therapies, and additional periurethral procedures are considered not medically necessary after five unsuccessful injections; product availability and some agents have been discontinued or removed.

"Use of injectable bulking agents for the treatment of urinary incontinence"

Sign up to see full coverage criteria, indications, and limitations.